| scholarly article | Q13442814 |
| P50 | author | Hisato Kawakami | Q56515885 |
| P2093 | author name string | Hidetoshi Hayashi | |
| Kazuhiko Nakagawa | |||
| Takeshi Yoshida | |||
| Kimio Yonesaka | |||
| Takao Tamura | |||
| Junji Tsurutani | |||
| Masayuki Takeda | |||
| Hiroto Ueda | |||
| Naoki Takegawa | |||
| Satomi Watanabe | |||
| Yoshikane Nonagase | |||
| Yasutaka Chiba | |||
| Koji Haratani | |||
| Junko Tanizaki | |||
| Takayuki Takahama | |||
| P2860 | cites work | Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3 | Q24309266 |
| SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion | Q24323616 | ||
| Cell signaling by receptor tyrosine kinases | Q24598357 | ||
| Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer | Q27853134 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential | Q28235606 | ||
| HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer | Q28476604 | ||
| Trastuzumab emtansine: mechanisms of action and drug resistance | Q33759627 | ||
| ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling | Q33886341 | ||
| ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors | Q34424780 | ||
| Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. | Q34554455 | ||
| Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer | Q34608899 | ||
| Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate | Q34880994 | ||
| The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells | Q35068059 | ||
| Molecular architecture of the ErbB2 extracellular domain homodimer | Q35176414 | ||
| Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers | Q35583019 | ||
| Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer | Q35742383 | ||
| Survivin regulation of vascular injury | Q36483564 | ||
| An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models | Q37690880 | ||
| Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib | Q38876644 | ||
| Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells | Q39083094 | ||
| Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. | Q39085623 | ||
| Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification. | Q39557421 | ||
| Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance | Q40109415 | ||
| Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest | Q40599574 | ||
| Advances in Targeting HER3 as an Anticancer Therapy | Q41621146 | ||
| Prognostic value of ERBB family mRNA expression in breast carcinomas | Q43461671 | ||
| Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways | Q44127144 | ||
| P433 | issue | 51 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | 84860-84871 | |
| P577 | publication date | 2016-12-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1 | |
| P478 | volume | 7 |
| Q37728639 | Chimeric antigen receptor T cells: a novel therapy for solid tumors |
| Q52581752 | Current therapeutic landscape for advanced gastroesophageal cancers. |
| Q48177736 | DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. |
| Q89683058 | Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance |
| Q90310892 | ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin |
| Q98158761 | Extramammary Paget's disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies |
| Q53691004 | HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. |
| Q64882619 | Identification of key pathways and genes in response to trastuzumab treatment in breast cancer using bioinformatics analysis. |
| Q64279893 | Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer |
Search more.